AZN vs LUNG

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

Pulmonx Corporation (LUNG) presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive earnings. While the company maintains strong short-term liquidity (Current Ratio 5.07) and impressive gross margins (74.19%), these are offset by negative revenue growth (-4.90%) and severe long-term price erosion (-96.7% over 5 years). The stark divergence between the analyst target price ($5.17) and the bearish insider activity suggests a speculative environment where fundamental deterioration outweighs theoretical upside.